Biofrontera AG (BFFTF)
Biofrontera AG operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Leverkusen, DE. The stock last traded at $0.33, down 95.24% on the session, giving a market capitalisation of $19.3M. On trailing twelve-month figures it carries a trailing P/E of -1.10, a net margin of -25.7%. Its beta of 0.59 implies it has historically moved less than the broad market.
Biofrontera AG operates as a biopharmaceutical enterprise, dedicated to the exploration, evolution, and commercialization of dermatological therapies. Its flagship offerings, Ameluz and the BF-RhodoLED lamp, are utilized for treating mild to moderate actinic keratoses on the face and scalp, managing field cancerization, and addressing life-threatening squamous cell carcinoma. The company is also advancing RhodoLED XL, intended for extensive interspersed lesions, and provides Belixos, an innovative cosmetic product designed for sensitive and irritated skin. Furthermore, Biofrontera develops Xepi, an agent targeting infections from antibiotic-resistant bacteria. The company primarily markets its solutions across the United States, Europe, and Israel, and maintains a collaborative and partnership agreement with Maruho Co., Ltd. Founded in 1997, Biofrontera AG's corporate headquarters are situated in Leverkusen, Germany.
Biofrontera AG is most often compared with the following Healthcare names: